All In Biotech

Drug Trial Radar · NCT07287189

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

51

Planned (sponsor's estimate)

Start

Dec 8, 2025

Primary completion

Mar 31, 2027

Study completion Feb 28, 2028

Sponsor

Lead sponsor
Satellos Bioscience, Inc.Industry
Sponsor type
Industry
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 7 years, up to 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial has two parts. In Part 1, the trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy. In Part 2, the trial will study two doses of SAT-3247 for an additional 9 months.

Conditions

  • Duchenne Muscular Dystrophy
  • Duchenne
  • DMD
  • Neuromuscular Diseases
  • Muscular Dystrophies

Interventions

  • SAT-3247Drug

    SAT-3247 is a selective AAK1 inhibitor for oral tablet administration which promotes functional rescue of asymmetric satellite cell division, resulting in the robust production of muscle progenitor cells, subsequent improvement in muscle regeneration, and enhanced muscle function.

  • PlaceboDrug

    matching placebo oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of SAT-3247Time frame: 12 weeks in Part 1 and up to 12 months in part 2
  2. Tolerability of SAT-3247Time frame: 12 weeks in Part 1 and up to 12 months in Part 2
  3. SAT-3247 effects on muscle strengthTime frame: 12 weeks in Part 1 and up to 12 months in Part 2

Locations

20 sites in 8 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California

  • Colorado Children's

    Aurora, Colorado

  • Lurie Children's

    Chicago, Illinois

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • Washington University

    St Louis, Missouri

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Seattle Children's

    Seattle, Washington

  • Children's Hospital at Westmead

    Westmead, New South Wales, Australia

  • Royal Children's Hospital Melbourne

    Melbourne, Victoria, Australia

  • Hôpital De La Citadelle (CHR)

    Liège, Liège, Belgium

  • UZ Gent

    Ghent, Oost-Vlaanderen, Belgium

  • Children's Hospital Eastern Ontario

    Ottawa, Ontario, Canada

  • Instytut Centrum Zdrowia Matki Polki

    Lodz, Łódź Voivodeship, Poland

  • Klinika Neurologii Rozwojowej Uniwersyteckie

    Gdansk, Pomeranian Voivodeship, Poland

  • University Children's Clinic Tirsova

    Belgrade, Serbia, Serbia

  • Mother and Child Health Care Institute

    Belgrade, Serbia, Serbia

  • Hospital Infantil i Hospital de la Dona

    Barcelona, Spain

  • Hospital Universitario Donostia

    Donostia / San Sebastian, Basque Country, Spain

  • Hospital Universitario y Politécnico La Fe

    Valencia, Valencia, Spain

  • Great Ormond Street

    London, UK, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.